The U.S. should begin pricing discussions for a COVID-19 vaccine before we get “stuck paying dearly for shots that the rest of the world will get much cheaper,” the author of a recent opinion piece published in The New York Times writes.
Elisabeth Rosenthal, author and editor and chief of Kaiser Health News, writes that while other countries have deployed strategies for managing drug prices, the U.S. continues to allow drugmakers to set a drug’s price.
“Drug companies deserve a reasonable profit for taking on this urgent task of creating a Covid-19 vaccine,” she writes. “But we deserve a return, too.”
To read the full opinion piece, click here. (Paid subscription may be required)